Sign in to view content

Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD

Robert L. Avery, MD

Video
Published 2021

Related

Primary Analysis Results of the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab (PDS) for Patients With Neovascular AMD
Peter A. Campochiaro, MD
Updates from the Field
2020
Episode 198: Journal Club about Online Physician Reviews, Systematic Review Reliability, SCORE2 24 month Data, Brolucizumab FDA Approval
Jayanth Sridhar, MD
Member Podcasts
2019
2-Year Outcomes From Randomized Trials of Anti-VEGF Treatments for Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME)
Geeta A. Lalwani, MD
Annual Meeting Talks
2018

Category: AMD-Neovascular

See more